Home  /  Resource Library  /  IBRUTINIB-RITUXIMAB VERSUS PLACEBO-RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 3 PERSPECTIVE STUDY

IBRUTINIB-RITUXIMAB VERSUS PLACEBO-RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 3 PERSPECTIVE STUDY

ICML 2025